Royalty Pharma plc (NASDAQ:RPRX) Holdings Increased by Aurora Investment Counsel

Aurora Investment Counsel increased its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,441 shares of the biopharmaceutical company’s stock after purchasing an additional 512 shares during the quarter. Aurora Investment Counsel’s holdings in Royalty Pharma were worth $1,427,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Swedbank AB raised its holdings in shares of Royalty Pharma by 30.6% during the second quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock valued at $285,151,000 after acquiring an additional 2,533,570 shares during the period. Van ECK Associates Corp raised its holdings in shares of Royalty Pharma by 171.1% during the third quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after acquiring an additional 64,057 shares during the period. Canada Pension Plan Investment Board raised its holdings in shares of Royalty Pharma by 5.2% during the first quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock valued at $28,051,000 after acquiring an additional 45,839 shares during the period. Summit Global Investments acquired a new stake in shares of Royalty Pharma during the third quarter valued at approximately $735,000. Finally, Tidal Investments LLC raised its holdings in shares of Royalty Pharma by 28.2% during the first quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 19,834 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Performance

RPRX stock opened at $26.22 on Thursday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $15.45 billion, a price-to-earnings ratio of 13.59, a P/E/G ratio of 4.59 and a beta of 0.47. Royalty Pharma plc has a 12 month low of $25.10 and a 12 month high of $31.66. The firm has a 50 day moving average of $27.35 and a two-hundred day moving average of $27.41.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.20%. Royalty Pharma’s payout ratio is presently 43.52%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RPRX. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, The Goldman Sachs Group boosted their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.